Investigation launched into Nuvalent's $10.6B deal with GSK over possible board breaches and unfair terms

Ademi LLP is investigating Nuvalent's $10.6 billion sale to GSK, alleging possible breaches of fiduciary duty by Nuvalent's board. The deal offers Nuvalent shareholders $124 per share, but insiders stand to gain extra benefits. The transaction also includes restrictions that penalize competing bids, raising concerns about fairness. The investigation focuses on whether the board acted in shareholders' best interests during the sale process.